<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Brush border Myosin Ia (MYO1A) has been shown to be frequently mutated in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> with microsatellite instability (MSI) and to have <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor activity in <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we investigated the frequency of frameshift mutations in the A8 microsatellite in exon 28 of MYO1A in MSI gastric and <z:e sem="disease" ids="C0014170" disease_type="Neoplastic Process" abbrv="">endometrial tumors</z:e> and found a high mutation rate in gastric (22/47; 46.8%) but not endometrial (3/48; 6.2%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Using a regression model, we show that MYO1A mutations are likely to confer a growth advantage to gastric, but not <z:e sem="disease" ids="C0014170" disease_type="Neoplastic Process" abbrv="">endometrial tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The mutant MYO1A(7A) protein was shown to lose its membrane localization in <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> cells and a <z:chebi fb="0" ids="27641">cycloheximide</z:chebi>-chase assay demonstrated that the mutant MYO1A(7A) protein has reduced stability compared to the <z:mp ids='MP_0002169'>wild type</z:mp> MYO1A </plain></SENT>
<SENT sid="4" pm="."><plain>Frequent MYO1A promoter hypermethylation was also found in <z:e sem="disease" ids="C0038356" disease_type="Neoplastic Process" abbrv="">gastric tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Promoter methylation negatively correlates with MYO1A <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in a series of 58 non-MSI gastric <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> (Pearson's r = -0.46; p = 0.0003) but not in a cohort of 54 non-MSI <z:e sem="disease" ids="C0014170" disease_type="Neoplastic Process" abbrv="">endometrial tumors</z:e> and treatment of <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> cells showing high MYO1A promoter methylation with the demethylating agent <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi>, resulted in a significant increase of MYO1A <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels </plain></SENT>
<SENT sid="6" pm="."><plain>We found that <z:mpath ids='MPATH_458'>normal</z:mpath> gastric epithelial cells, but not <z:mpath ids='MPATH_458'>normal</z:mpath> endometrial cells, express high levels of MYO1A </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, when considered together, our findings suggest that MYO1A has <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor activity in the <z:mpath ids='MPATH_458'>normal</z:mpath> gastric epithelium but not in the <z:mpath ids='MPATH_458'>normal</z:mpath> endometrium and inactivation of MYO1A either genetically or epigenetically may confer gastric epithelial cells a growth advantage </plain></SENT>
</text></document>